Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2018

Ngo Anna, Koay Ann, Pecquet Christian, Diaconu Carmen C, Jenkins David A, Shiau Andrew K, Constantinescu Stefan N, Choong Meng Ling

Abstract excerpt

An inhibitor for the thrombopoietin receptor (TpoR) would be more specific for the treatment of myeloproliferative neoplasms (MPNs) due to constitutively active mutant TpoR compared to the current treatment approach of inhibiting Janus kinase 2 (JAK2). We describe a cell-based high-throughput phenotypic screening approach to identify inhibitors for constitutively active mutant TpoR. A stepwise elimination process...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Drug Evaluation, Preclinical

Share to Ligands

Share to Luminescent Measurements

Share to Receptors, Thrombopoietin

Share to Small Molecule Libraries

Source

Identifiers

PMID: 29736709
DOI: 10.1007/978-1-4939-7847-2_4

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.PMID 29736709Read ↗

A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms.Semantic proximity Read ↗

In vitro assays and techniques utilized in anticancer drug discoverySemantic proximity Read ↗

Development of Drug-resistant Cell Lines for Experimental ProceduresSemantic proximity Read ↗

Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening.Semantic proximity Read ↗

Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.Semantic proximity Read ↗

Phenotypic screening in cancer drug discovery - past, present and future.Semantic proximity Read ↗

Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven activation from cytokine-induced stimulation.Semantic proximity Read ↗

A phenotypic screen identifies a compound series that induces differentiation of acute myeloid leukemia cells <i>in vitro</i> and shows anti-tumour effects <i>in vivo</i>Semantic proximity Read ↗

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell deathSemantic proximity Read ↗

A Phenotypic Screen Identifies a Compound Series That Induces Differentiation of Acute Myeloid Leukemia Cells In Vitro and Shows Antitumor Effects In Vivo.Semantic proximity Read ↗

Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysSemantic proximity Read ↗

Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.